Cell Therapy Catalysts Will Reshape Long Term Prospects For Severe Inflammatory And Cardiovascular Diseases

Catalysts

About Mesoblast

Mesoblast develops and commercializes mesenchymal stromal cell therapies for severe inflammatory and cardiovascular conditions.

What are the underlying business or industry changes driving this perspective?

• The first and only FDA approved mesenchymal stromal cell product in the U.S., Ryoncil, together with over 1,100 patents and established commercial scale manufacturing, positions Mesoblast to benefit if cell therapies gain wider medical adoption. This would be most visible in revenue growth and operating leverage.
• Expanding Ryoncil from pediatric to adult steroid refractory acute GvHD through an NIH backed pivotal trial with the Bone Marrow Transplant Clinical Trials Network targets a patient pool described as roughly 3x the size of the current pediatric population. This could materially influence product revenue and help absorb fixed commercial costs, supporting net margins.
• Planned development of Ryoncil in biologic refractory inflammatory bowel disease, where an unmet need remains for early and durable remission in a multi billion dollar addressable market, gives Mesoblast a route into a much larger chronic indication. If successful, this would mainly affect long term revenue scale and earnings power.
• The chronic low back pain Phase III program for rexlemestrocel L targets millions of patients and a setting where opioid use is common, aligning the product with an ongoing healthcare shift toward non opioid therapies. If the program succeeds, it could contribute substantially to diversified revenue and reduce reliance on a single product.
• The heart failure program for rexlemestrocel L, with RMAT designation and FDA feedback that existing trial data could support an accelerated approval filing alongside a planned confirmatory study, gives Mesoblast a potential entry into a very large cardiovascular market. Outcomes would primarily influence long term revenue scale and the path to sustainable earnings.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Mesoblast's revenue will grow by 204.5% annually over the next 3 years.
• Analysts assume that profit margins will increase from -593.9% today to 45.8% in 3 years time.
• Analysts expect earnings to reach $222.1 million (and earnings per share of $0.23) by about January 2029, up from $-102.1 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $615.2 million in earnings, and the most bearish expecting $49.2 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 22.1x on those 2029 earnings, up from -22.3x today. This future PE is greater than the current PE for the US Biotechs industry at 18.8x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.84%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Ryoncil is still in the early phase of its commercial rollout with US$11.3 million in reported net sales against net operating cash spend of US$50 million. If demand from pediatric acute GvHD centers grows more slowly than expected or plateaus after early adopters, the business could remain heavily cash consuming for longer, putting pressure on earnings and potentially forcing dilution through equity or additional financing, which would affect earnings per share.
• The long term story leans heavily on label expansions and new indications, including adult acute GvHD, inflammatory bowel disease, chronic low back pain and heart failure. Several of these are only at the pivotal trial planning or enrollment stage and rely on regulatory alignment that could shift, so any delay, negative readout or change in FDA requirements would push out potential revenue streams and keep net margins and earnings under strain.
• Rexlemestrocel L in chronic low back pain and heart failure targets very large patient populations where entrenched treatment patterns such as opioids, biologics and device or surgical interventions are deeply embedded. Even with supportive data it may take sustained physician education, payer engagement and behavior change for sales to build, which could limit the revenue contribution from these assets relative to current expectations and slow any improvement in operating leverage.
• Although Ryoncil currently benefits from being the first and only FDA approved mesenchymal stromal cell product with over 1,100 patents and patent applications, cell therapy is an active research field. New entrants, alternative modalities or improved biologics could erode pricing power or share of future indications, which would pressure long term revenue potential and constrain the path to higher net margins.
• The company benefits today from broad U.S. reimbursement including Medicaid in all states and favorable policies from major commercial payers. Over time, changes to reimbursement rules, J code rates or payer views of cost effectiveness for high cost therapies could lead to tighter coverage criteria or lower effective pricing, which would weigh on revenue growth, reduce gross margin from the current 90% level on product sales and limit the expansion of overall earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of A$3.83 for Mesoblast based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of A$4.71, and the most bearish reporting a price target of just A$3.11.
  
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $485.4 million, earnings will come to $222.1 million, and it would be trading on a PE ratio of 22.1x, assuming you use a discount rate of 6.8%.
  
• Given the current share price of A$2.64, the analyst price target of A$3.83 is 31.1% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.